Related Experiment Video
Updated: Jul 11, 2026

A Proximal Culture Method to Study Paracrine Signaling Between Cells
Published on: August 28, 2018
HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway
Maria E Ramos-Nino1, Steven R Blumen, Tara Sabo-Attwood
1University of Vermont College of Medicine, Department of Pathology, 89 Beaumont Avenue HSRF#216, Burlington, VT 05405, USA. Maria.Ramos@uvm.edu
Abstract:
The ligand hepatocyte growth factor/scatter factor (HGF) and its receptor tyrosine kinase, c-Met, are highly expressed in most human malignant mesotheliomas (MMs) and may contribute to their increased growth and viability. Based upon our observation that RNA silencing of fos-related antigen 1 (Fra-1) inhibited c-met expression in rat mesotheliomas (1), we hypothesized that Fra-1 was a key player in HGF-induced proliferation in human MMs. In three of seven human MM lines evaluated, HGF increased Fra-1 levels and phosphorylation of both extracellular signal-regulated kinase 5 (ERK5) and AKT that were inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitor, LY290042. HGF-dependent phosphorylation and Fra-1 expression were decreased after knockdown of Fra-1, whereas overexpression of Fra-1 blocked the expression of mitogen/extracellular signal-regulated kinase kinases (MEK)5 at the mRNA and protein levels. Stable MM cell lines using a dnMEK5 showed that basal Fra-1 levels were increased in comparison to empty vector control lines. HGF also caused increased MM cell viability and proliferating cell nuclear antigen (PCNA) expression that were abolished by knockdown of MEK5 or Fra-1. Data suggest that HGF-induced effects in some MM cells are mediated via activation of a novel PI3K/ERK5/Fra-1 feedback pathway that might explain tumor-specific effects of c-Met inhibitors on MM and other tumors.
Insights
Hepatocyte growth factor (HGF) drives malignant mesothelioma (MM) growth via a novel pathway involving ERK5 and Fra-1. Inhibiting this pathway may offer new MM treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Hepatocyte growth factor (HGF) and its receptor c-Met are highly expressed in malignant mesotheliomas (MMs).
- HGF/c-Met signaling may promote MM growth and survival.
- Fos-related antigen 1 (Fra-1) was previously shown to inhibit c-Met expression in rat mesotheliomas.
Purpose of the Study:
- To investigate the role of Fra-1 in HGF-induced proliferation in human MMs.
- To elucidate the signaling pathway mediating HGF effects in MMs.
Main Methods:
- Human MM cell lines were treated with HGF.
- RNA silencing (knockdown) and overexpression of Fra-1 were performed.
- Expression of Fra-1, ERK5, AKT, and MEK5 was analyzed at mRNA and protein levels.
- Cell viability and proliferating cell nuclear antigen (PCNA) expression were assessed.
- Stable MM cell lines with dominant-negative MEK5 (dnMEK5) were generated.
Main Results:
- HGF increased Fra-1 levels and phosphorylation of ERK5 and AKT in some MM lines.
- These effects were inhibited by a PI3K inhibitor (LY290042).
- Fra-1 knockdown decreased HGF-dependent phosphorylation and Fra-1 expression.
- Fra-1 overexpression blocked MEK5 expression.
- dnMEK5 expression led to increased basal Fra-1 levels.
- HGF-induced MM cell viability and PCNA expression were abolished by MEK5 or Fra-1 knockdown.
Conclusions:
- HGF-induced MM cell proliferation and viability are mediated by a novel PI3K/ERK5/Fra-1 feedback pathway.
- This pathway may explain the tumor-specific effects of c-Met inhibitors in MMs and other cancers.
Related Concept Videos
Mitogens and the Cell Cycle
MAPK Signaling Cascades
Hedgehog Signaling Pathway
Regulation of Angiogenesis and Blood Supply
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
TGF - β Signaling Pathway

